Research Summary
Somatropin is a recombinant form of human growth hormone composed of 191 amino acids, identical to endogenous pituitary growth hormone and extensively studied in endocrine research.
Evidence profile
Human Phase 3 evidence
10 cited publications · 2 primary trials
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Deal CL et al. · The Journal of clinical endocrinology and metabolism · 2022
The study reportedThe efficacy of once-weekly somatrogon was noninferior to once-daily somatropin, with similar safety and tolerability profiles. (ClinicalTrials.gov no. NCT02968004).
Thornton PS et al. · The Journal of clinical endocrinology and metabolism · 2021
The study reportedThe trial met its primary objective of noninferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.
Zhang J et al. · Scientific reports · 2025
The study reportedPEG-rhGH showed superior efficacy to DGH at 12 months and comparable efficacy at other time points. The safety profiles were similar for the two treatments.
Ouyang R et al. · Frontiers in medicine · 2025
The study reportedThis bibliometric analysis highlights the progression of rhGH research for ISS, shifting from foundational studies to contemporary priorities such as tailored therapies and clinical outcomes.
Crabbé R et al. · Journal of endocrinological investigation · 2008
The study reportedThere is a clear dose-response relationship for r-hGH in the treatment of short children born SGA and the analysis confirmed that treatment with Serono r-hGH formulation 0.033 mg/kg/day should provide a meaningful therapeutic response.
Maghnie M et al. · The Journal of clinical endocrinology and metabolism · 2022 · PMID 36102184
Pricci F et al. · BMC endocrine disorders · 2022 · PMID 35241041
Shi Y et al. · Frontiers in endocrinology · 2022 · PMID 36589818
Huang L et al. · Frontiers in pharmacology · 2025 · PMID 40799818
Zhong X et al. · Frontiers in endocrinology · 2025 · PMID 41282298
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.
Somatropin is a prescription-only medicine in many jurisdictions and is presented here solely in a scientific research context.